MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature's Translational Psychiatry JournalGlobeNewsWire • 06/21/21
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryGlobeNewsWire • 06/07/21
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in EuropeGlobeNewsWire • 05/06/21
MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryGlobeNewsWire • 03/09/21
MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual ConferenceGlobeNewsWire • 03/08/21
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in JapanGlobeNewsWire • 01/18/21
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment PartnersGlobeNewsWire • 01/12/21
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MSGlobeNewsWire • 12/29/20
MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis JournalGlobeNewsWire • 11/25/20